Cambrex Corporation (NYSE:CBM) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Saturday.

A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. ValuEngine cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Cambrex Corporation presently has a consensus rating of “Buy” and an average price target of $64.00.

Cambrex Corporation (NYSE CBM) traded down 0.85% during trading on Friday, reaching $52.80. The company’s stock had a trading volume of 191,728 shares. Cambrex Corporation has a one year low of $38.30 and a one year high of $62.95. The firm has a market cap of $1.73 billion, a PE ratio of 19.23 and a beta of 2.28. The company has a 50-day moving average of $58.46 and a 200 day moving average of $55.48.

Cambrex Corporation (NYSE:CBM) last posted its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.76. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The firm had revenue of $134.55 million for the quarter, compared to analysts’ expectations of $136.82 million. During the same quarter in the prior year, the company posted $0.68 earnings per share. The business’s revenue for the quarter was up 13.4% on a year-over-year basis. Analysts expect that Cambrex Corporation will post $3.08 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/12/cambrex-corporation-cbm-stock-rating-lowered-by-bidaskclub.html.

In other news, VP Samantha Hanley sold 14,000 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $57.56, for a total transaction of $805,840.00. Following the sale, the vice president now owns 1,500 shares in the company, valued at $86,340. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $54.19, for a total transaction of $650,280.00. Following the sale, the chief executive officer now owns 95,328 shares in the company, valued at approximately $5,165,824.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 70,656 shares of company stock worth $4,064,423. Corporate insiders own 2.48% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. OxFORD Asset Management LLP bought a new stake in shares of Cambrex Corporation during the second quarter valued at about $4,670,000. Dimensional Fund Advisors LP boosted its stake in shares of Cambrex Corporation by 0.9% in the second quarter. Dimensional Fund Advisors LP now owns 1,330,254 shares of the biotechnology company’s stock valued at $79,483,000 after buying an additional 11,762 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Cambrex Corporation by 32.5% in the second quarter. Renaissance Technologies LLC now owns 254,202 shares of the biotechnology company’s stock valued at $15,189,000 after buying an additional 62,402 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Cambrex Corporation by 5.4% in the second quarter. Parametric Portfolio Associates LLC now owns 93,817 shares of the biotechnology company’s stock valued at $5,606,000 after buying an additional 4,841 shares in the last quarter. Finally, Advisor Group Inc. boosted its stake in shares of Cambrex Corporation by 29.8% in the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 615 shares in the last quarter. Hedge funds and other institutional investors own 98.28% of the company’s stock.

About Cambrex Corporation

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.